Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_18_suppst18.xlsx › Sheet1
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M et al.
Molecular Cancer Therapeutics, 2022
BAP1 loss defines a new class of renal cell carcinoma.
Peña-Llopis S et al.
Nature Genetics, 2012
22683710 (PubMed )
Supplement: NIHMS377160-supplement-Suppl__Data_2.xlsx › Suppl._Data_2
Select a paper to view details